Loading
Genetic Therapy / Alzheimer Disease / Disease Models, Animal · Journal article
Brain Research · July 23, 2026
Encouraging direction, but not yet definitive.
This preclinical study demonstrates that FGF17 delivery via AAV9 or exogenous protein reduces Aβ deposition, neuronal apoptosis, and cognitive impairment in APP/PS1 transgenic mice through FGFR3/PI3K/AKT signaling activation. The findings support further investigation of FGF17 as a disease-modifying approach but require human efficacy validation before clinical translation.
Preclinical mechanistic study: in vitro cell model, transgenic mouse model, and pathway analysis. AD patients (serum only), human SH-SY5Y neuroblastoma cells, transgenic APP/PS1 mice with Alzheimer's-like pathology. Intervention: AAV9-mediated FGF17 gene delivery (stereotactic injection) or exogenous human recombinant FGF17 protein administration. Compared with: Control (untreated or vehicle); FGFR3 inhibitor used to test pathway specificity.
Diminished FGF17 concentrations observed in serum of individuals with AD AAV9-mediated FGF17 gene delivery alleviated cognitive impairment of APP/PS1 mice FGF17 treatment reduced abnormal Aβ deposition and neuronal apoptosis in treated models
No long-term safety or tolerability data presented for AAV9 delivery or recombinant protein administration
These findings are preliminary and preclinical. While the pathway and cellular/animal data are encouraging, human efficacy has not been tested. Clinicians should await powered clinical trials before considering FGF17-based interventions as a therapeutic option.
A mechanistic study in cell and transgenic mouse models showing FGF17 delivery reduces Aβ deposition and apoptosis with pathway confirmation, but lacking human efficacy data and powered clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
These findings are preliminary and preclinical. While the pathway and cellular/animal data are encouraging, human efficacy has not been tested. Clinicians should await powered clinical trials before considering FGF17-based interventions as a therapeutic option.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aims. We explore a possible association between dysregulated FGF17 expression and the pathogenesis underlying AD, and discovery efficacious therapeutic strategies.Methods. We measured FGF17 levels in serum from AD patients, and selected APP/PS1 mice as well as SH-SY5Y cells stimulated with Aβ1-42 for 24 h as the AD model. Through AAV9-mediated gene delivery (stereotactic injection) or exogenous human recombinant protein administering, we investigated the effects of FGF17 on cell apoptosis phenotype, synaptic defects, and behavioral manifestations.Results. Our investigation demonstrated diminished FGF17 concentrations in the serum of individuals with AD. Comparable reductions in FGF17 levels appeared in SH-SY5Y cells treated with Aβ1-42 over a 24-hour period, as well as in APP/PS1 mouse brains. Subsequent experiments demonstrated that AAV9-mediated FGF17 gene delivery could alleviate the cognitive impairment of APP/PS1 mice. Moreover, abnormal Aβ deposition and neuronal apoptosis were reduced through FGF17 treatment; the strategy inhibited neuronal damage and synaptic defects. Concurrently, we confirmed that in the aforementioned biological process, the FGFR3/PI3K/AKT signaling pathway was activated. Inhibiting FGFR3 reduced the protective effect of FGF17.Conclusions. This study highlights the promising disease-modifying therapies for FGF17 in managing AD. Our research indicates that the approach plays a positive role in both cognitive function and histopathology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.